icon-    folder.gif   Conference Reports for NATAP  
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
HIV Attachment Inhibitor Fostemsavir / BMS-663068, GSK3684934
  Fostemsavir (BMS-663068) is an experimental HIV entry inhibitor and a prodrug of temsavir (BMS-626529).
Other Names: BMS-663068, GSK3684934, fostemsavir tromethamine, prodrug of BMS-626529, prodrug of GSK2616713, prodrug of temsavir
Drug Class: Entry Inhibitor
Registry Number: 864953-29-7 (CAS)
Chemical Name: Piperazine,
Company: ViiV Healthcare
Phase of Development: III
HIV-1 Attachment Inhibitor Prodrug BMS-663068:
Interactions with Rifabutin, with or without Ritonavir, in Healthy
ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets
- HIV attachment & maturation

The late stage R&D assets include an attachment inhibitor (BMS-663068) investigated in Phase III as a breakthrough therapy candidate for heavily treatment-experienced patients. The other two assets are maturation inhibitors. The first one (BMS-955176) is in Phase IIb research for treatment-naïve and treatment-experienced patients, with the second (BMS-986173) being a back-up candidate. A transitional services agreement will be in place to manage the transfer of the assets following completion of the deal with Bristol-Myers Squibb.
The acquisition of Bristol-Myers Squibb's HIV discovery programmes includes a novel biologic treatment with a triple mechanism of action (BMS-986197), a maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor. As part of the agreement, a number of Bristol-Myers Squibb drug discovery employees will be offered the opportunity to transfer to ViiV Healthcare. Bristol-Myers Squibb will continue to provide some support to the discovery programmes pursuant to a service agreement.